December 15th, 2020 | 15:37 CET
Moderna, AdTiger, AstraZeneca - here we go!
Table of contents:
AdTiger - Digital market booming
Advertising is placed where the customer is. Due to the Corona pandemic and the recurring lockdowns, more and more people migrated away from the offline to the online marketplace. As a result, eCommerce sales worldwide are expected to grow between 15% and 20% this year. Advertising platforms are responsible for ensuring that the customer sees the right things, personalized just for him, in the banners or displays. One of the interesting players is the Chinese advertising platform AdTiger. AdTiger's primary goal is to connect Chinese advertisers who operate internationally with the biggest social media platforms and apps, mainly from the US.
Partnerships with the big players
The Chinese partners read like the crème de la crème of the social media industry. For example, AdTiger is a China Export Partner (CEP) of Facebook and ranked first among Facebook's 23 CEP's in terms of ad spend on Facebook's ad inventory in 2019, and also has an agreement with Google in the AdWords Reseller Program. With Baidu, AdTiger is an authorized Snapchat sales representative. Direct cooperations are also in place with Yahoo and the emerging platform TikTok. Thus, there is enormous potential for the Chinese to direct their customers to all relevant channels.
Expansion of Big Data and Artificial Intelligence
To target advertising correctly, AdTiger uses its own specially programmed software, AdTensor. The program uses artificial intelligence to perform ad optimization and ad management automatically, intelligently, and in real-time. AdTensor's Big Data and AI capabilities make it possible to achieve optimal advertising goals for advertisers. It also helps to leverage the monetization potential of media publishers. Analysis and tracking in the field of artificial intelligence are to be expanded further. For example, AdTiger plans to make a significant addition to its Big Data team this year. The Company's shares have recently been trading at a current price of EUR 0.13 on the Frankfurt Stock Exchange. The market capitalization is currently just under EUR 80.0 million.
AstraZeneca - Record deal in the bag
To expand its business with drugs for rare diseases, AstraZeneca is prepared to put the internal record sum of USD 39 billion on the table for the US biotech Company Alexion. For the acquisition, AstraZeneca plans to pay USD 175 per Alexion share in cash as well as in its securities. The British pharmaceutical Company hopes that this will generate synergies of USD 500 million per year from the end of the third year of the takeover. Above all, profits are expected to bubble up. Double-digit percentage growth in core earnings per share is expected in the first three years after completion of the transaction.
Analysts are less optimistic than the Company itself about the largest acquisition in the Company's history. According to Goldman Sachs, while the proposed deal improves cash inflow dynamics and provides a reasonable degree of diversification, the experts see a risk of diluted and potentially lower organic growth. Investors also took the news negatively, at least in the short term. The share opened with a minus of over 9% but was able to halve the losses in the course of trading.
Moderna - Start in the USA
What is currently still having a negative impact on the share price is the uncertain forecast as to when the British will submit an application for approval of their vaccine. Here, the competitors BioNTech and Pfizer, as well as the US Company Moderna, are months ahead. After an emergency approval by the health authority FDA, the delivery of the Corona vaccine of the Mainz-based pharmaceutical Company BioNTech and its US partner Pfizer is underway in the United States. Freight company FedEx said Sunday that its subsidiary FedEx Express would begin transporting the vaccine, which is frozen with dry ice.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.